RxDoctor Payments Data

Steven Galen, MD

Internal Medicine · Los Angeles, CANPI 1396702320

Payments from drug & device makers

$11,539in general payments, 2019–2025

Across 459 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Dexcom, Inc.$981
  • Lilly USA, LLC$794
  • Novo Nordisk$662
  • AstraZeneca$628
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$11,512100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,539 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$199,655
Medicare patients
355
Services billed
6,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$110,276
Repatha SureclickEvolocumab88$85,844
JardianceEmpagliflozin24$42,827
EliquisApixaban26$37,825
ProliaDenosumab18$30,747
MounjaroTirzepatide13$17,401
UbrelvyUbrogepant11$16,319
LinzessLinaclotide14$14,087
Testosterone54$12,369
RybelsusSemaglutide13$11,661
XareltoRivaroxaban12$6,323
OxycontinOxycodone Hcl13$6,016
BelsomraSuvorexant12$4,996
SymbicortBudesonide/Formoterol Fumarate21$4,866
SynthroidLevothyroxine Sodium44$4,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$662$121,93793 claims
Boehringer IngelheimJardiance$398$42,82724 claims
PfizerEliquis, Paxlovid$474$39,25456 claims
AbbVieUbrelvy, Linzess, Synthroid$2,169$34,60169 claims
AmgenProlia$1,126$30,74718 claims
Lilly USA, LLCMounjaro$794$17,40113 claims
Johnson & JohnsonXarelto$136$6,32312 claims
MerckBelsomra$256$4,99612 claims
AstraZenecaSymbicort$628$4,86621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →